You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Auristatin

Showing 1 - 25 of 102
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial (Antibody-Drug Conjugate)

Not yet recruiting
  • Cancer
  • Antibody-Drug Conjugate
  • (no location specified)
Aug 23, 2023

Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

Not yet recruiting
  • Breast Cancer
  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
  • (no location specified)
Feb 22, 2023

Advanced Malignant Solid Tumors Trial in Beijing (9MW2821)

Recruiting
  • Advanced Malignant Solid Tumors
  • Beijing, Beijing, China
  • +1 more
Mar 6, 2023

Solid Tumors Trial in Shanghai (9MW2821)

Recruiting
  • Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 14, 2022

Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)

Recruiting
  • Carcinoma
  • +2 more
  • RC48-ADC and JS001
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023

Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Enfortumab vedotin
  • Kansas City, Kansas
    University of Kansas Cancer Center
Jun 23, 2023

Advanced Malignancies Trial in Guangzhou (BRY812 for injection)

Not yet recruiting
  • Advanced Malignancies
  • BRY812 for injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital，Sun Yat-sen University
Sep 7, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Advanced Solid Tumor, Urinary Bladder Tumor, Pancreatic Tumors Trial in Worldwide (BT8009, Nivolumab)

Recruiting
  • Advanced Solid Tumor
  • +4 more
  • Denver, Colorado
  • +20 more
Nov 22, 2022

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Advanced or Metastatic Solid Malignancies Trial in United States (Sitravatinib, Nivolumab, Pembrolizumab)

Enrolling by invitation
  • Advanced or Metastatic Solid Malignancies
  • Beverly Hills, California
  • +12 more
Aug 23, 2022

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

Non Small Cell Lung Cancer, Urothelial Cancer, Ovarian Cancer Trial in United States (XB002, Nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +9 more
  • Saint Louis, Missouri
  • +4 more
Dec 12, 2022

Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors Trial run by the National

Not yet recruiting
  • Adenocarcinoma of the Bladder
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

Diffuse, Large B-Cell, Lymphoma Trial in China (Polatuzumab Vedotin, Bendamustine, Rituximab)

Completed
Has Results
  • Diffuse, Large B-Cell, Lymphoma
  • Polatuzumab Vedotin
  • +3 more
  • Beijing, China
  • +9 more
Jul 7, 2022

Advanced Solid Tumours Trial (EBC-129, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumours
  • (no location specified)
Jan 18, 2023

Urothelial Carcinoma, HER2-expressing Trial in Beijing (RC48-ADC, Toripalimab, Gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • HER2-expressing
  • Beijing, Beijing, China
  • +1 more
Apr 2, 2022

Melanoma, Stage II, HER2-positive, Advanced Melanoma Trial (RC48-ADC)

Not yet recruiting
  • Melanoma, Stage II
  • +2 more
  • (no location specified)
Nov 29, 2021

Diffuse Large B Cell Lymphoma Trial (Polatuzumab Vedotin)

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
May 3, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer Trial in

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • Orange, California
  • +5 more
May 4, 2022

Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma Trial in Zhengzhou, Wuhan,

Recruiting
  • Advanced or Metastatic Gastric Cancer
  • Advanced or Metastatic Gastroesophageal Junction Carcinoma
  • Zhengzhou, Henan, China
  • +4 more
Jan 10, 2022

DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Gemcitabine)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +3 more
  • Hollywood, Florida
  • +89 more
Jan 31, 2023